These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 29502862)

  • 1. Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha as a Novel Target for Bipolar Disorder and Other Neuropsychiatric Disorders.
    Nierenberg AA; Ghaznavi SA; Sande Mathias I; Ellard KK; Janos JA; Sylvia LG
    Biol Psychiatry; 2018 May; 83(9):761-769. PubMed ID: 29502862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders.
    Agarwal S; Yadav A; Chaturvedi RK
    Biochem Biophys Res Commun; 2017 Feb; 483(4):1166-1177. PubMed ID: 27514452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unlocking new avenues for neuropsychiatric disease therapy: the emerging potential of Peroxisome proliferator-activated receptors as promising therapeutic targets.
    Dey AD; Mannan A; Dhiman S; Singh TG
    Psychopharmacology (Berl); 2024 Aug; 241(8):1491-1516. PubMed ID: 38801530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines.
    Fakan B; Szalardy L; Vecsei L
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer's Disease and Other Neurodegenerative Disorders.
    Wójtowicz S; Strosznajder AK; Jeżyna M; Strosznajder JB
    Neurochem Res; 2020 May; 45(5):972-988. PubMed ID: 32170673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PGC-1α sparks the fire of neuroprotection against neurodegenerative disorders.
    Lv J; Jiang S; Yang Z; Hu W; Wang Z; Li T; Yang Y
    Ageing Res Rev; 2018 Jul; 44():8-21. PubMed ID: 29580918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisom proliferator-activated receptor-γ coactivator-1α in neurodegenerative disorders: A promising therapeutic target.
    Yang YN; Zhang MQ; Yu FL; Han B; Bao MY; Yan-He ; Li X; Zhang Y
    Biochem Pharmacol; 2023 Sep; 215():115717. PubMed ID: 37516277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome Proliferator-activated Receptor Gamma Coactivator-1 Alpha: A Double-edged Sword in Prostate Cancer.
    Zheng K; Chen S; Hu X
    Curr Cancer Drug Targets; 2022; 22(7):541-559. PubMed ID: 35362394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis.
    Szalardy L; Zadori D; Bencsik K; Vecsei L; Klivenyi P
    Neurosci Lett; 2017 Jun; 651():128-133. PubMed ID: 28483651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiepileptic Drug-Activated Constitutive Androstane Receptor Inhibits Peroxisome Proliferator-Activated Receptor
    Shizu R; Otsuka Y; Ezaki K; Ishii C; Arakawa S; Amaike Y; Abe T; Hosaka T; Sasaki T; Kanno Y; Miyata M; Yamazoe Y; Yoshinari K
    Mol Pharmacol; 2020 Nov; 98(5):634-647. PubMed ID: 32892155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational Design, Synthesis, and In Vitro Neuroprotective Evaluation of Novel Glitazones for PGC-1α Activation via PPAR-γ: a New Therapeutic Strategy for Neurodegenerative Disorders.
    Justin A; Mandal S; Prabitha P; Dhivya S; Yuvaraj S; Kabadi P; Sekhar SJ; Sandhya CH; Wadhwani AD; Divakar S; Bharathi JJ; Durai P; Prashantha Kumar BR
    Neurotox Res; 2020 Mar; 37(3):508-524. PubMed ID: 31782098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PPAR regulatory system in cardiac physiology and disease.
    Finck BN
    Cardiovasc Res; 2007 Jan; 73(2):269-77. PubMed ID: 17010956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minutes of PPAR-γ agonism and neuroprotection.
    Prashantha Kumar BR; Kumar AP; Jose JA; Prabitha P; Yuvaraj S; Chipurupalli S; Jeyarani V; Manisha C; Banerjee S; Jeyabalan JB; Mohankumar SK; Dhanabal SP; Justin A
    Neurochem Int; 2020 Nov; 140():104814. PubMed ID: 32758586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glitazones Activate PGC-1α Signaling via PPAR-γ: A Promising Strategy for Antiparkinsonism Therapeutics.
    P P; Justin A; Ananda Kumar TD; Chinaswamy M; Kumar BRP
    ACS Chem Neurosci; 2021 Jul; 12(13):2261-2272. PubMed ID: 34125534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.
    Aleshin S; Strokin M; Sergeeva M; Reiser G
    Neurochem Int; 2013 Oct; 63(4):322-30. PubMed ID: 23811400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders.
    Jamwal S; Blackburn JK; Elsworth JD
    Pharmacol Ther; 2021 Mar; 219():107705. PubMed ID: 33039420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PGC-1alpha, a new therapeutic target in Huntington's disease?
    McGill JK; Beal MF
    Cell; 2006 Nov; 127(3):465-8. PubMed ID: 17081970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of Chinese herbs and its effective components on coronary heart disease through PPARs-PGC1α pathway.
    Wang Q; Li C; Zhang Q; Wang Y; Shi T; Lu L; Zhang Y; Wang Y; Wang W
    BMC Complement Altern Med; 2016 Dec; 16(1):514. PubMed ID: 27955667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Strategy of Targeting Peroxisome Proliferator-Activated Receptor (PPAR) in the Treatment of Neuropsychiatric Disorders.
    Matrisciano F; Pinna G
    Adv Exp Med Biol; 2023; 1411():513-535. PubMed ID: 36949324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PGC-1α, Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.
    Lloret A; Beal MF
    Neurochem Res; 2019 Oct; 44(10):2423-2434. PubMed ID: 31065944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.